Journal of pain & palliative care pharmacotherapy
-
J Pain Palliat Care Pharmacother · Feb 2025
UK Medical Cannabis Registry: An Analysis of Clinical Outcomes of Medicinal Cannabis Therapy for Cancer Pain.
Cancer pain (CP) is a prevalent condition with limited pharmacotherapeutic options. Cannabis-based medicinal products (CBMPs) have shown analgesic effects, but their efficacy in CP remains contentious. This study aims to evaluate the change in patient-reported outcome measures (PROMs) and adverse events (AEs) in CP patients treated with CBMPs. ⋯ Improvements in GAD-7, SQS, and EQ-5D-5L index scores were also observed (p < 0.050). Twenty-nine AEs (17.26%) were reported by five patients (2.98%), mostly mild-to-moderate (72.41%). Although the observational design means causality cannot be established, the findings support the development of future randomized controlled trials into CP management with CBMPs.
-
J Pain Palliat Care Pharmacother · Feb 2025
Evaluation of Low-Dose Naltrexone for Chronic Pain Management.
Naltrexone is an opioid antagonist approved by the Food and Drug Administration (FDA) for alcohol use disorder and opioid use disorder. More recently, naltrexone has been used off-label at low doses of 4.5 mg daily for chronic pain due to fibromyalgia, neuropathy, complex regional pain syndrome, and multiple sclerosis. While several studies show the promise of low-dose naltrexone in treating chronic pain, most had small sample sizes and short-term follow up, which warrants additional investigation into the effectiveness of low-dose naltrexone. ⋯ The average change in pain score from initiation to most recent visit was -0.83. Low-dose naltrexone was generally well-tolerated with 32% (13 of 41) of Veterans reporting adverse effects including vivid dreams, drowsiness, dizziness, and nausea. Low-dose naltrexone resulted in a small decrease in pain, although may be considered after a patient has failed multiple lines of therapy for additional pain control after a risk versus benefits discussion.
-
J Pain Palliat Care Pharmacother · Jan 2025
A Comparative Study Between Hydrodilatation and Intra-Articular Corticosteroid Injection in Patients with Shoulder Adhesive Capsulitis: A Single-Blinded Randomized Clinical Trial.
This study compares the efficacy of hydrodilatation (HD) alone with intra-articular corticosteroid injection (ICI) in treating frozen shoulder (FS). A total of 48 patients with FS were randomly assigned to two groups: 24 patients received HD treatment, while the other 24 patients received ICI treatment. HD involved 20 mL 0.9% normal saline solution with 3 mL 2% lidocaine, and ICI included 1 mL of 40 mg/mL methylprednisolone acetate with 1 mL 2% lidocaine and 3 mL normal saline. ⋯ However, no significant differences were found in between groups comparison at study end (p > 0.05), with no significant interaction between groups and times (p > 0.05). Absolute changes from baseline to eight-week follow-up were not significantly different between HD and ICI (p > 0.05). In the short term, HD alone demonstrates strong efficacy in managing FS, matching the effectiveness of ICI.
-
J Pain Palliat Care Pharmacother · Jan 2025
Opioid Allergy Cross-Reactivity: A Retrospective Study Across Three Opioid Classes.
IgE-mediated opioid hypersensitivities, or true allergies, are rare and most adverse reactions to opioids can be attributed to side effects or to pseudo-allergies. Given that immune-mediated allergies to opioids are uncommon, literature regarding cross-reactivity among opioid classes are limited. This retrospective study aimed to determine the rates of cross-reactivity and tolerance among patients with previously documented opioid allergy or adverse drug reaction (ADR) across three opioid drug classes (natural, semisynthetic, and synthetic opioids). ⋯ A total of 1507 patients were identified with previously documented allergy or ADR to at least one opioid and at least one subsequent opioid drug exposure. No cross-reactivity among any of the opioid drug classes were found resulting in 100% re-exposure tolerance rates with all study arms. These findings could increase confidence in utilizing opioids in patients with historically documented opioid allergies or ADRs.
-
J Pain Palliat Care Pharmacother · Jan 2025
Peripheral Edema as an Adverse Drug Reaction to Mirtazapine in an Oral Cavity Cancer Patient Receiving Palliative Care at Tertiary Care Centre: A Case Report.
Mirtazapine is a selective serotonergic antidepressant that functions by blocking adrenergic alpha2-autoreceptors and heteroreceptors and inhibiting 5-HT2 and 5-HT3 receptors. It is a noradrenergic drug. Mirtazapine has anxiolytic or sleep-quality-improving effects, aggravates appetite-stimulation, and has stomach emptying functions. ⋯ The peripheral edema completely resolved after stopping mirtazapine. To the best of our knowledge, this is the first instance of a patient with advanced oral cavity cancer experiencing peripheral edema as a result of receiving mirtazapine medication. Our study will assist medical professionals in identifying the potential use of mirtazapine in situations where peripheral edema develops quickly, facilitating its quick clearance.